Skip to main content

MNPR

Stock
Health Care
Biotechnology

Performance overview

MNPR Price
Price Chart

Forward-looking statistics

Beta
0.52
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.

Company info

SectorHealth Care
IndustryBiotechnology
Employees15
Market cap$14.2M

Fundamentals

Enterprise value$164.2M
Revenue$0.0
Revenue per employee
Profit margin0.00%
Debt to equity0.00

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$3.98
Dividend per share
Revenue per share$0.00
Avg trading volume (30 day)$2M
Avg trading volume (10 day)$4M
Put-call ratio

Macro factor sensitivity

Growth+7.4
Credit+32.6
Liquidity-20.3
Inflation-0.1
Commodities+2.6
Interest Rates+3.2

Valuation

Dividend yield0.00%
PEG Ratio-15.36
Price to sales
P/E Ratio-15.36
Enterprise Value to Revenue
Price to book4.14

Upcoming events

Next earnings dayMay 13, 2025
Next dividend day
Ex. dividend day

News

Wall Street Analysts Predict a 51.26% Upside in Monopar Therapeutics (MNPR): Here's What You Should Know

The mean of analysts' price targets for Monopar Therapeutics (MNPR) points to a 51.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Investment Research (June 11, 2025)
Up 600% Then Down 50% In 2 Days: What Is Going On With MNPR Stock?

The stock price of Monopar Therapeutics (NASDAQ: MNPR), a clinical-stage biopharmaceutical company, skyrocketed from levels of $5.25 on Monday, October 21, to $32.66 on Thursday, October 24, before falling to around $17 now. The 6x rise in a matter of days can be attributed to a major licensing development for Monopar.

Forbes (October 28, 2024)
Monopar Therapeutics Stock Jumps 4X, Inks Licensing Pact With AstraZeneca For Once Terminated Phase 3 Candidate For Rare Genetic Disorder

Monopar Therapeutics Inc. MNPR stock is skyrocketing on Thursday.

Benzinga (October 24, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free